GMI Research analysis indicates that the Insulin Delivery Devices Market estimated at USD 12.5 billion in 2021 and is slated to register a healthy CAGR of 7.5% over the forecast period, and is projected to reach USD 22.3 billion in 2029.

To have an edge over the competition by knowing the market dynamics and current trends of “Insulin Delivery Devices Market”, request for Sample Report here

Key Drivers

The global insulin delivery devices market is gaining traction over the coming years. The drastic rise in the number of diabetic patients has been the primary driving factors responsible for the strong demand of the market. According to the Centers for Disease Control and Prevention (CDC), around 29.1 million people in the U.S. have diabetes and approximately 4.6 – 9.2% of pregnant women are affected by gestational diabetes.

The manufacturers around the world are emphasizing on bringing technological advancement in the insulin delivery systems to gain a competitive edge over the other leading players. For example, Novo Nordisk, a multinational pharmaceutical company, launched its first insulin pen, NovoPen Echo in the U.S. market. With the accelerating penetration of the internet, the consumers have become more aware regarding the different delivery devices available in the market. The insulin pen provides enhanced efficiency, has a longer lifespan, and offers better dosing accuracy, particularly at low doses.

The drastic change in the lifestyle pattern of the consumers is the major reason for accelerated number diabetes cases. Patients now prefer syringes and insulin pens rather than the traditional insulin devices as they are highly cost-effective, easily available, and offers numerous refining policies for compensation. The continued rising demand for advanced insulin devices will have a long-term positive effect on the market. Despite of the current COVID-19 pandemic, the global market for insulin delivery devices remains stable. As the governments of different regions have already announced total lockdown and temporary shutdown of industries, the diabetes patients are largely adopting the method of self-monitoring and insulin delivery at their home by using advanced insulin devices, such as insulin pens and syringes.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Product Type – Segment Analysis

Insulin pens are expected to dominate the insulin delivery market over the forecast period. Increasing inclination towards insulin pens owing to the remarkable features which include improved life quality, patient satisfaction, user-friendliness, etc. Increasing emphasis of producers on encouraging the innovations and advancements is estimated to augment the market growth. For instance, in January 2014, Novo Nordisk introduced a new device, NovoPen Echo in the U.S. with a memory function and half-unit dosage features. Thus, the product advancements are projected to strengthen the market over the forthcoming years. As per the U.S. claims database insulin pen have better adherence and possess the ability to restrict the financial burden of diabetes over vial & syringe.

End-use – Segment Analysis

Home care segment is anticipated to lead the insulin delivery market over the forecast period, because of the growing awareness about diabetes care and rising adoption of these devices in the home care settings. Growing emphasis to minimize incremental healthcare expenses concerned with diabetes management, ongoing innovations, and availability of user friendly devices are some factors bolstering the market growth. The use of insulin devices at home saves on visiting costs, hospital or clinic fees, and waiting time, which fuels the market growth.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Figure 2: Global Insulin Delivery Devices Market Revenue, by Region, 2017

Source: GMI Research

For detailed scope of the “Insulin Delivery Devices Market” report request a Sample Copy of the report

Regional – Segment Analysis

North America is estimated to witness a tremendous growth over the forecast period, because of the ongoing technological advancements and existence of leading players. The large pool of diabetic population and easy availability of technologically advanced devices are projected to augment the regional growth. As per the report by CDC in 2016, nearly 29 million people in the U.S. suffered from diabetes, amongst which 21.0 million patients were diagnosed and 8.1 million patients remained undiagnosed.

Asia Pacific insulin delivery devices market is expected to grow at a faster CAGR during the forecast period, owing to the existence of large population base suffering from diabetes and its rising awareness amongst individuals. In addition, various leading vendors have extended their business in Asia Pacific and are offering high-end products for diabetes care, which adds to the market expansion.

Top Market Players

Various notable players operating in global insulin delivery devices market include Abbott Laboratories, Ypsomad Holding AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, Insulet Corporation, Medtronic, Animas Corporation, Becton, Dickinson and Company, Dexcom, Inc., Sanofi, among others.

Key Developments:

• • In 2022, Novo Nordisk introduced its smart insulin in the UK, which helped people treat the NHS for diabetes access to devices. This latest product will offer competitive advantage and strengthen its industrial position in the UK region.
  • In 2022, Boston-based Insulet Corp. declared that the FDA (Food and Drug Administration) cleared the new Omnipod 5 system, helping the companies enter into the automated insulin delivery (AID) universe.
  • In 2020, Medtronic introduced the InPen smart insulin pen incorporated with real-time Guardian Connect CGM data. This integrated machinery offers real-time glucose readings along with the insulin dose data, which helps in reaching smart dosing decisions. This product launch will help the company in increasing sales & revenue generation in insulin delivery devices market.

Segments covered in the Report:

The global insulin delivery devices market has been segmented on the basis of product type, end user and key regions. Based on product type, the market comprises of Insulin Pens, Insulin Pumps, Pen Needles, Insulin Syringes and Others. The end user segment includes, Patients/Homecare and Hospitals & Clinics.

Key questions answered in this research report:

• • At what pace is global Insulin Delivery Devices market growing? What will be the growth trend in the future?
  • What are the key drivers and restraints in Insulin Delivery Devices market? What will be the impact of drivers and restraints in the future?
  • What are the regional revenues and forecast breakdowns? Which are the major regional revenue pockets for growth in the global Insulin Delivery Devices market?
  • Which Product Type generated maximum revenues in 2021 and identify the most promising Product Type during the forecast period?
  • What are the various End User areas of global Insulin Delivery Devices market and how they are poised to grow?
  • What companies are the major participants in this market and their business strategies, how does the competitive landscape look like?

Report Coverage	Details
Market Revenues (2021)	USD 12.5 billion
Market Base Year	2021
Market Forecast Period	2022-2029
Base Year & Forecast Units	Revenues (USD Billion)
Market Segment	By Product Type, By End User, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	Abbott Laboratories, Ypsomad Holding AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, Insulet Corporation, Medtronic, Animas Corporation, Becton, Dickinson and Company, Dexcom, Inc., Sanofi., among others; a total of 11 companies covered.
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

Market Segmentation

Global Insulin Delivery Devices Market by Product Type

• • Insulin Pens
    • Reusable Insulin Pens
    • Disposable Insulin Pens
  • Insulin Pumps
    • External/Tethered Pumps
    • Patch Pumps
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Insulin Syringes
  • Others

Global Insulin Delivery Devices Market by End User

• • Patients/Homecare
  • Hospitals & Clinics

Global Insulin Delivery Devices Market by Region

• • North America Insulin Delivery Devices Market (Option 1: As a part of the free 25% customization)
    • By Product Type
    • By End User
    • US Market All-Up
    • Canada Market All-Up
  • Europe Insulin Delivery Devices Market (Option 2: As a part of the free 25% customization)
    • By Product Type
    • By End User
    • UK Market All-Up
    • Germany Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up
  • Asia-Pacific Insulin Delivery Devices Market (Option 3: As a part of the free 25% customization)
    • By Product Type
    • By End User
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up
  • RoW Global Insulin Delivery Devices Market (Option 4: As a part of the free 25% customization)
    • By Product Type
    • By End User
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Major Players Operating the Insulin Delivery Devices (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Abbott Laboratories
  • Ypsomad Holding AG
  • F. Hoffmann-La Roche Ltd
  • Terumo Corporation
  • Insulet Corporation
  • Medtronic
  • Animas Corporation
  • Becton
  • Dickinson and Company
  • Dexcom, Inc.
  • Sanofi